← back to search

Matthias Leisegang

German Cancer Research Center · DE
Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, and Cancer Immunotherapy and Biomarkers.
h-index
22
citations
1,622
works
66
NIH funding
primary concept
email

Recent publications

A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies
Blood 2025cited by 2position: middledoi
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire
Journal for ImmunoTherapy of Cancer 2025cited by 2position: lastdoi
Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry
Blood 2024cited by 21position: middledoi
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Clinical Cancer Research 2024cited by 13position: lastdoi
CD4 <sup>+</sup> T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy
Science Immunology 2024cited by 7position: middledoi
Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system
Frontiers in Immunology 2024cited by 3position: middledoi
Oligonucleotide library screening for identification of virus‐specific T‐cell receptors
European Journal of Immunology 2024cited by 1position: middledoi
A systematic safety pipeline for selection of T-cell receptors to enter clinical use
npj Vaccines 2023cited by 20position: middledoi
ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes
Molecular Immunology 2023cited by 7position: middledoi
Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3
Cancers 2023cited by 6position: middledoi
Rapid single-cell identification of Epstein–Barr virus-specific T-cell receptors for cellular therapy
Cytotherapy 2022cited by 14position: middledoi
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Nature Biotechnology 2021cited by 34position: middledoi
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma
OncoImmunology 2021cited by 33position: middledoi
Cooperation of genes in HPV16 <i>E6/E7</i>-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens
Carcinogenesis 2020cited by 12position: middledoi
Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma
OncoImmunology 2019cited by 36position: middledoi
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer
Clinical Cancer Research 2018cited by 79position: middledoi
Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells
Oncotarget 2018cited by 59position: middledoi
Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus
Clinical Cancer Research 2018cited by 26position: middledoi
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
Nature 2017cited by 263position: middledoi
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
Cancer Research 2017cited by 39position: middledoi
Targeting human melanoma neoantigens by T cell receptor gene therapy
Journal of Clinical Investigation 2016cited by 58position: firstdoi
Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice
Nature Biotechnology 2015cited by 96position: middledoi
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation
Clinical Cancer Research 2015cited by 83position: firstdoi
HEK293-Based Production Platform for γ-Retroviral (Self-Inactivating) Vectors: Application for Safe and Efficient Transfer of <i>COL7A1</i> cDNA
Human Gene Therapy Clinical Development 2014cited by 20position: middledoi
P72. Transgenic expression of a chimeric signaling receptor to facilitate T cell costimulation in the tumour environment
Journal for ImmunoTherapy of Cancer 2014cited by 0position: middledoi
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo
Blood 2012cited by 60position: middledoi
Human Antitumor CD8+ T Cells Producing Th1 Polycytokines Show Superior Antigen Sensitivity and Tumor Recognition
The Journal of Immunology 2012cited by 38position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Kazuma Kiyotani · National Institute of Biomedical Innovation, Health and Nutrition9 papers (2015–2024)Thomas Blankenstein · Helmholtz Association of German Research Centres8 papers (2015–2025)Wolfgang Uckert · Humboldt-Universität zu Berlin8 papers (2012–2017)Gerald Willimsky · Charité - Universitätsmedizin Berlin5 papers (2017–2025)Hans Schreiber · University of Chicago5 papers (2015–2025)Steven P. Wolf · University of Chicago4 papers (2020–2025)Leonie Rosenberger · Charité - Universitätsmedizin Berlin4 papers (2022–2025)Leo Hansmann · University Hospital Regensburg4 papers (2022–2025)Taigo Kato · Osaka City University4 papers (2018–2025)Yusuke Nakamura · National Institute of Biomedical Innovation, Health and Nutrition4 papers (2018–2025)Makiko Harada · OncoTherapy Science (Japan)4 papers (2018–2021)Dolores J. Schendel · Ludwig-Maximilians-Universität München4 papers (2012–2017)Karin Schreiber · Guy's and St Thomas' NHS Foundation Trust4 papers (2015–2024)Poh Yin Yew · Kanagawa Prefectural Hospital Organization4 papers (2015–2025)Lars Bullinger · University of Gothenburg3 papers (2022–2024)Vasiliki Anastasopoulou · Academy of Athens3 papers (2024–2025)Carlotta Welters · Charité - Universitätsmedizin Berlin3 papers (2022–2024)Tatsuo Matsuda · Okayama University Hospital3 papers (2018–2019)Kimberley Drousch · Charité - Universitätsmedizin Berlin3 papers (2023–2025)Thomas Kammertöns · Berlin Institute of Health at Charité - Universitätsmedizin Berlin3 papers (2022–2024)